FGP
SPRY icon

Freestone Grove Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Freestone Grove Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$16 – 1294
2026
Q1 		$16 Sell
2
-28,001
-100% -$268K ﹤0.01% 940
2025
Q4 		$326K Sell
28,003
-124,194
-82% -$1.21M ﹤0.01% 647
2025
Q3 		$1.53M Buy
+152,197
New +$2.18M 0.01% 391
2025
Q1 		– Sell
-12,501
Closed -$132K – 773
2024
Q4 		$132K Buy
+12,501
New +$175K ﹤0.01% 552

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Freestone Grove Partners's SPRY Position: Q2 2026 in Review

Freestone Grove Partners sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 2 shares — an estimated $16 sold.

Freestone Grove Partners first reported a position in SPRY in Q4 2024 and held it in 4 quarters. The position peaked at $1.53M in Q3 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Freestone Grove Partners reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 2 ARS Pharmaceuticals shares in Q2 2026, an estimated $16.
  • Freestone Grove Partners first reported a position in ARS Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Freestone Grove Partners's ARS Pharmaceuticals position peaked at $1.53M in Q3 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.